Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

EA Pharma Sells Calcimimetic to Startup for Dialysis Hormone

publication date: Aug 21, 2024

EA Pharma sold global rights for a small molecule calcimimetic that may control intact parathyroid hormone levels in patients with secondary hyperparathyroidism receiving hemodialysis. Upacicalcet is an intravenous therapy. EA Pharma, a subsidiary of Eisai Pharma of Japan, sold the rights to North Carolina’s Pathalys Pharma, a biopharma that develops best-in-class therapies for chronic kidney diseases. At the same time, Pathalys received an initial seed financing from DaVita Venture Group, and Catalys Pacific. Catalys Pacific is a Tokyo-San Francisco investor. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here